<DOC>
	<DOCNO>NCT01350817</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety treatment sequential erlotinib plus docetaxel therapy versus docetaxel alone second line treatment patient recurrent non-small cell lung cancer . Patients randomize receive group 1 ( experimental arm ) : docetaxel :75 mg/m² IV day 1 every 3 week erlotinib:150 mg/d per o d2-d16 group 2 ( control arm ) : docetaxel :75 mg/m² IV day 1 every 3 week . The anticipated time study treatment disease progression . Target sample size 156 . The main study determine relevance association sequential erlotinib docetaxel term progression-free survival .</brief_summary>
	<brief_title>Erlotinib Docetaxel Second Line Treatment Patients With Non Small Cell Lung Cancer</brief_title>
	<detailed_description>In study , patient randomize group 1 ( experimental arm ) : docetaxel :75 mg/m² IV day 1 every 3 week erlotinib:150 mg/d per o d2-d16 group 2 ( control arm ) : docetaxel :75 mg/m² IV day 1 every 3 week . Assessment treatment : Physical examination , ECG , : every 3 week , laboratory test : weekly , every 3 week pulmonary X-ray .The CT scan : . Measurable target assess RECIST compare begin treatment : 6 week ( day 42 EVA 2 ) , 12 week ( D84 EVA 3 ) , 15 week ( D105 EVA 4 : Evaluation SSP ) every 6 week progression . Quality life assess Day 42 every 6 week chemotherapy , Tolerability assess visit base CTC v4.0 criterion .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically prove NSCLC ( Mutational status EGFR : wild type unknown Stage IV disease cytologic histologic documentation patient single easily accessible metastasis metastatic relapse non irradiated region primary tumor treat surgery radiotherapy ( cytologic histologic documentation relapse ) Presence least one measurable target lesion ( one dimension ) non irradiate region ( least 10 mm spiral compute tomography ) . Age ≥ 18 year Performance status 0,1,2 exception : age &gt; 74 year PS 0 1 Normal hepatic function Normal renal function Normal calcemia Normal haematological function Life expectancy &gt; 12 week . Women child bear potential must use effective contraception . Men might surgically sterile accept use effective contraceptive procedure 6 month treatment . Written inform consent participate study . PS &gt; 2 , exception : age &gt; 74 year PS ≥ 2 Presence another cancer Previous treatment anti egfr agent docetaxel QT prolongation ( &gt; 470 m ) Uncontrolled arterial hypertension . Concurrent radiotherapy , except palliative bone irradiation . Stroke le 6 month study entry . Psychiatric neurological disorder prevent patient understanding nature trial Uncontrolled infection . Caval syndrome Other organic disorder prevent inclusion trial Malabsorption syndrome Allergy erlotinib one constituent Allergy docetaxel one constituent Pregnancy breastfeed Surgery le two month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>